Author

P. Amengual-Rigo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:proteomics· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:rat· 1

Frequent Co-Authors

A. Barajas· 2 shared A. Pons-Grifols· 2 shared A. Valencia· 2 shared B. Clotet· 2 shared B. Trinite· 2 shared C. Aguilar-Gurrieri· 2 shared C. Rovirosa· 2 shared F. Tarres-Freixas· 2 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Barajas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintSep 7, 2023

VLP-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice

A. Barajas, P. Amengual-Rigo, A. Pons-Grifols…·J. Blanco

This study develops a neoantigen selection pipeline and a VLP-based vaccine platform to enhance immunogenicity and antitumor activity in mice.

DOI 10.1101/2023.09.07.556652

mouseproteomics

𝕏 PostBluesky

ImmunologybioRxivJul 7, 2023

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

J. Carrillo, C. Avila-Nieto, J. Vergara-Alert…·J. Segales

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

DOI 10.3389/fimmu.2023.1291972

𝕏 PostBluesky